Endo International PLC (NASDAQ:ENDP) traded down 0.9% during mid-day trading on Friday . The company traded as low as $19.21 and last traded at $20.05, with a volume of 6,611,683 shares trading hands. The stock had previously closed at $20.23.

A number of equities research analysts recently issued reports on the company. JMP Securities reaffirmed a “buy” rating and issued a $52.00 target price (down previously from $56.00) on shares of Endo International PLC in a research note on Sunday, May 8th. Barclays PLC reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, May 8th. Deutsche Bank AG reissued a “buy” rating and set a $30.00 price target on shares of Endo International PLC in a research note on Wednesday, June 29th. Leerink Swann reissued a “market perform” rating and set a $23.00 price target on shares of Endo International PLC in a research note on Wednesday, June 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $26.00 price target on shares of Endo International PLC in a research note on Wednesday, May 18th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the stock. Endo International PLC presently has a consensus rating of “Hold” and a consensus price target of $39.95.

The stock’s market capitalization is $4.42 billion. The company has a 50-day moving average price of $20.03 and a 200-day moving average price of $24.80.

Endo International PLC (NASDAQ:ENDP) last issued its earnings results on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.12. During the same period last year, the business earned $1.08 EPS. The company had revenue of $921 million for the quarter, compared to analyst estimates of $873.50 million. The company’s quarterly revenue was up 25.3% on a year-over-year basis. Analysts anticipate that Endo International PLC will post $4.56 EPS for the current fiscal year.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.